<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493064</url>
  </required_header>
  <id_info>
    <org_study_id>06-21</org_study_id>
    <nct_id>NCT00493064</nct_id>
  </id_info>
  <brief_title>To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions</brief_title>
  <official_title>Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palo Alto Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palo Alto Medical Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Niacin, a B vitamin, may act as a
      vasodilator to encourage earlier formation of collateral blood vessels that may serve to
      bypass the obstructed vein in the eye. The topical steroid eye drops are aimed at reducing
      swelling in the retina, until the collateral vessels have a chance to develop.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to develop a less risky, yet effective and more sustainable
      treatment for retinal vein occlusions than the current commonly used approach of repeated
      intravitreal triamcinolone acetonide (Kenalog) injections. The types of retinal vein
      occlusion that are being studied include central (CRVO), hemi-retinal (HRVO), and branch
      (BRVO) retinal vein occlusion. Niacin, (Nicotinic Acid, not Nicotinamide)a B-vitamin, has
      lipid lowering and vasodilating properties. The combination of Niacin and Prednisolone
      Acetate steroid eye drops as a non-invasive treatment approach was developed by the Principal
      Investigator. The Niacin dilates the retinal vessels, hopefully encouraging earlier
      collateral vessel formation aimed at bypassing the venous obstruction, thus restoring venous
      outflow. The Prednisolone Acetate steroid eye drops are aimed at reducing vascular leakage
      and therefore the macular edema in the eye while the Niacin is taking effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart.</measure>
    <time_frame>one year</time_frame>
    <description>improvement with combination of niacin and topical prednisolone acetate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Decrease in the Thickness of the Retina</measure>
    <time_frame>one year</time_frame>
    <description>data not available</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Prospective active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niacin 500mg TID PO for treatment of retinal vein occlusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinic acid</intervention_name>
    <description>topical eye drops</description>
    <arm_group_label>Prospective active treatment</arm_group_label>
    <other_name>Niacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone acetate</intervention_name>
    <description>topical eye drops</description>
    <arm_group_label>Prospective active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to understand the study procedures, agree to participate, and
             give written consent.

          -  Patient must have central retinal vein occlusion, hemi-retinal vein occlusion or
             branch retinal vein occlusion.

          -  Patients must be able to follow the study medication regimen.

          -  Patients must agree to return for the once monthly eye exams.

          -  Patients must agree to have liver function tests performed on a regular basis.

          -  Patients must agree to have regular appointments with their Internist on an
             established basis.

        Exclusion Criteria:

          -  Patients with active Gout, or high levels of Uric

          -  Patients may not be pregnant or lactating.

          -  The Principal Investigator reserves the right to exclude any patient who he feels will
             not make a good candidate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gaynon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palo Alto Medical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation Department of Ophthalmology</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>August 27, 2018</results_first_submitted>
  <results_first_submitted_qc>December 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2018</results_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prospective Active Treatment</title>
          <description>Niacin 500mg TID PO for treatment of retinal vein occlusions.
Nicotinic acid: topical eye drops
Prednisolone acetate: topical eye drops</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prospective Active Treatment</title>
          <description>Niacin 500mg TID PO for treatment of retinal vein occlusions.
Nicotinic acid: topical eye drops
Prednisolone acetate: topical eye drops</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart.</title>
        <description>improvement with combination of niacin and topical prednisolone acetate</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prospective Active Treatment</title>
            <description>Niacin 500mg TID PO for treatment of retinal vein occlusions.
Nicotinic acid: topical eye drops
Prednisolone acetate: topical eye drops</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart.</title>
          <description>improvement with combination of niacin and topical prednisolone acetate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Decrease in the Thickness of the Retina</title>
        <description>data not available</description>
        <time_frame>one year</time_frame>
        <population>Although data for this outcome measure was collected, however, data are not available. The PI is retired and no longer works in the organization. Sincere efforts were made to obtain the data, however, no data are available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prospective Active Treatment</title>
            <description>Niacin 500mg TID PO for treatment of retinal vein occlusions.
Nicotinic acid: topical eye drops
Prednisolone acetate: topical eye drops</description>
          </group>
        </group_list>
        <measure>
          <title>A Decrease in the Thickness of the Retina</title>
          <description>data not available</description>
          <population>Although data for this outcome measure was collected, however, data are not available. The PI is retired and no longer works in the organization. Sincere efforts were made to obtain the data, however, no data are available for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No information regarding the Adverse Events is available. The PI is retired and no longer works for the organization. Sincere efforts were made to obtain the data, however, no Adverse Events data are available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prospective Active Treatment</title>
          <description>Niacin 500mg TID PO for treatment of retinal vein occlusions.
Nicotinic acid: topical eye drops
Prednisolone acetate: topical eye drops</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Renee Kaneshiro, study coordinator</name_or_title>
      <organization>PaloAltoMF</organization>
      <phone>650-853-4744</phone>
      <email>kaneshr@pamf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

